IDH2 and central nervous system cancer: Primary glioma cells with IDH mutation (IDHmt) demonstrate significant sensitivity to BET inhibitors JQ1 and GS-626510, exhibiting half-maximal inhibitory concentrations (IC50) 1,000 times lower than that of Temozolomide.